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Historically ﬁlamentous bacteriophage have been known to be the workhorse of phage dis-
play due to their ability to link genotype to phenotype. More recently, the ﬁlamentous phage
scaffold has proven to be powerful outside the realm of phage display technology in ﬁelds
such as molecular imaging, cancer research and materials, and vaccine development. The
ability of the virion to serve as a platform for a variety of applications heavily relies on the
functionalization of the phage coat proteins with a wide variety of functionalities. Genetic
modiﬁcation of the coat proteins has been themost widely used strategy for functionalizing
the virion; however, complementary chemical modiﬁcation strategies can help to diversify
the range of materials that can be developed.This review emphasizes the recent advances
that have been made in the chemical modiﬁcation of ﬁlamentous phage as well as some
of the challenges that are involved in functionalizing the virion.
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INTRODUCTION
The Ff group of ﬁlamentous bacteriophage are non-lytic viruses
that infect bacteria by attachment to their F pili (Smith and
Petrenko, 1997; Kehoe andKay, 2005). M13, f1, and fd are themost
well-characterized types of this virus and have a DNA sequence
similarity up to 98.5% (Rakonjac et al., 2011). These viruses are
known to be the workhorses of phage display, as they can be
selected and evolved to identify novel binding activity through
repeated cycles of mutation, selection, and ampliﬁcation. This
methodology allows for the production of phage constructs that
can bind a variety of targets, including proteins, polymers, small
molecules, and metal ions (Smith and Petrenko, 1997; Kehoe
and Kay, 2005). In terms of structure, ﬁlamentous phage exist
as long, thin tubes with a large aspect ratio (∼900 nm in length
and 6 nm in width). The capsids comprise of ﬁve copies of
each minor coat protein (pIII, pVI, pVII, and pIX) and a vary-
ing amount of the major coat protein (pVIII; Li et al., 2010). The
interior of the virion contains a single-stranded deoxyribonucleic
acid (ssDNA) genome that is protected by the cylindrical protein
housing formed by the pVIII subunits. The minor coat proteins
form caps at both ends of the assembly and are involved in host
infection. The overall ﬁlamentous phage structure is shown in
Figure 1A.
In addition to their important role in molecular evolution, ﬁl-
amentous phage have served as attractive platforms for a wide
variety of applications due to their stability, ability to display
peptides with strong afﬁnities for their targets, and ease of pro-
duction by propagation in bacteria. Moreover, the high number
of repetitive coat proteins in the virion allow for multiple copies
of a desired functionality to be displayed with well-deﬁned spa-
tial relationships. Reported applications include light-harvesting
(Namet al., 2010), nanoparticle nucleation (Mao et al., 2004), elec-
trode templating (Lee et al., 2009), cell growth and differentiation
(Merzlyak et al., 2009), bactericidal agents (Hagens and Blasi,
2003), molecular imaging (Hajitou et al., 2006; Chen et al., 2007;
Li et al., 2010; Carrico et al., 2012; Ghosh et al., 2012), and
drug delivery (Bar et al., 2008; Suthiwangcharoen et al., 2011;
Ghosh et al., 2012).
The use of these virions in many applications requires the inte-
gration of targeting groups and/or cargo molecules that cannot
be biosynthesized. For example, early work used phage display
to evolve M13 phage coat proteins to bind semiconductors of
varied compositions and geometries (Whaley et al., 2000). Con-
tinued work in this ﬁeld has used similar techniques to develop
phage-based scaffolds that can serve as improved anodes in lithium
ion batteries, leading to enhanced storage capacity, improved
conductivity, and the ability to produce thin ﬂexible 2D arrays
(Lee et al., 2002; Nam et al., 2006; Avery et al., 2009). In addi-
tion, applications in the ﬁelds of drug delivery and medical
imaging have also relied heavily on the functionalization of ﬁl-
amentous phage particles with a range of synthetic molecules
(Deutscher and Kelly, 2011).
In early work, the genetic manipulation of the phage coat
proteins to incorporate peptides with novel function was the stan-
dard approach for ﬁlamentous phagemodiﬁcation (Willats, 2002).
More recently, bioconjugation techniques have been exploited to
allow a greater variety of synthetic molecules to be attached to
the phage. The incorporation of these bioconjugation techniques
has allowed for the production of a much more diverse set of
constructs. As examples, the phage scaffold has been successfully
modiﬁed with a variety of small organic molecules (Niu et al.,
2008; Carrico et al., 2012), quantum dots (Merzlyak et al., 2009),
ﬂuorophores (Goldman et al., 2000; Hilderbrand et al., 2005, 2008;
Carrico et al., 2012), and drugs (Yacoby et al., 2006; Bar et al.,
2008). Despite these accomplishments, however, there still exist
a limited number of chemical labeling strategies to modify the
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FIGURE 1 | Covalent modification strategies for filamentous phage.
(A)The general locations of the coat proteins are shown. Note that actual
phage have signiﬁcantly more copies of the pVIII protein than are shown.
Typical reactions that are used to modify speciﬁc functional groups on these
proteins are shown in (B–E). For each strategy, example references appear in
the brackets.
ﬁlamentous phage coat proteins. The most widely used strate-
gies rely on reagents that target reactive amino acid residues
present in the sequences (i.e., the N-terminus, lysines, cysteines,
tyrosines, aspartic acids, and glutamic acids). A summary of the
strategies that have been frequently used to modify the virion
is shown in Figure 1. As powerful as these modiﬁcation strate-
gies are, the majority of these techniques lack the high degree
of speciﬁcity and control that is needed for many applications.
The ideal bioconjugation reaction should be able to modify tar-
gets in a site-speciﬁc manner while still conserving the integrity of
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the construct by operating in aqueous media under mild pH and
temperature conditions.
With these considerations in mind, this review will focus on
the recent chemical modiﬁcation strategies that have been imple-
mented on ﬁlamentous phage formaterials construction. It should
be noted that several detailed discussions regarding the use of
ﬁlamentous phage in the context of phage display (Smith and
Petrenko, 1997; Kehoe and Kay, 2005), gene therapy (Verma and
Weitzman, 2005; Schaffer et al., 2008), and adjuvants for vac-
cines (Garcea and Gissmann, 2004) have appeared, and thus these
applications will not be emphasized in this review. In addition,
several in-depth reviews on the structure, replication cycle, and
general applications of the ﬁlamentous phage have been also pub-
lished elsewhere (Hemminga et al., 2010; Branston et al., 2011;
Rakonjac et al., 2011).
MAIN
GENETIC MODIFICATION OF THE COAT PROTEINS
The most widely used strategy for functionalizing the phage
scaffold has been the genetic incorporation of peptides that are
engineered to associate with a novel target or serve as reac-
tive handles (Rakonjac et al., 2011). It has been demonstrated
that each type of coat protein present on the ﬁlamentous phage
possesses the ability to display foreign proteins through genetic
modiﬁcation (Kwasnikowski et al., 2005; Smelyanski and Ger-
shoni, 2011; Ghosh et al., 2012). The minor pIII coat protein
is the most widely used to display protein motifs due to its
ability to tolerate a high number and variety of amino acid inser-
tions (Kwasnikowski et al., 2005). In applications where a large
loading capacity is desired, such as drug delivery or imaging,
it is common to label the major coat protein, pVIII, due to
its high copy number (approximately 2700 monomers for M13
and f1, and 4,200 monomers for fd). However, it is important
to note that genetic engineering of this major coat protein is
less common because the pVIII monomers can only tolerate the
incorporation of 6–8 amino acids (Popp et al., 2007; Hess et al.,
2012).
With the incorporation of peptide sequences onto the phage
scaffold comes the ability to modify the phage using either
enzyme-based ligation techniques or chemoselective bioconjuga-
tion reactions. The genetic incorporation of enzymatic ligation
handles has been demonstrated in several phage systems, includ-
ing the biotin ligase (Chen et al., 2007; Smelyanski and Gershoni,
2011) and sortase A (Hess et al., 2012) systems. These methods
are particularly useful in terms of their high degree of speciﬁcity
compared to chemical approaches. Alternatively, several examples
that use genetic modiﬁcation to incorporate an amino acid that
can act as a functional handle also exist. For example, genetically
incorporated cysteine residues have been shown to be modiﬁed
through native chemical ligation (Dwyer et al., 2000), thiol alky-
lation (Jespers et al., 2004; Heinis et al., 2009), and maleimide
modiﬁcation (Santoso et al., 2013). However, with these latter
strategies, one has to take great care in the placement of the
cysteine residues to limit problems with disulﬁde cross-linking
between the closely packed phage coat proteins. Furthermore,
the chemical modiﬁcation of introduced cysteines can result in
the unwanted labeling of endogenous solvent exposed cysteines
found on the phage coat proteins (pVI, pVII, pIX; Soumillion
et al., 1994; Pedersen et al., 1998). One way to circumvent these
difﬁculties is to use immobilized tris(2-carboxyethyl)phosphine
(iTCEP) to reduce only the sterically accessible cysteines on
a peptide sequence displayed on the pIII coat protein of the
phage (Jafari et al., 2014). Using this modiﬁcation strategy, the
Derda group was able to create a light-inhibited ligand sys-
tem by alkylating and reducing two cysteines on the pIII that
ﬂank a randomized heptamer peptide sequence that was incor-
porated into the phage by phage display. Although the genetic
incorporation of amino acids has proven to be a powerful tool
for installing peptide motifs and natural amino acids as func-
tional handles on the pIII protein, this strategy is limited to a
low number of modiﬁcations on phage if the major coat pro-
tein cannot tolerate these genetic insertions following the signal
sequence.
FREE AMINE MODIFICATION
One of the most widely used strategies for the chemical mod-
iﬁcation of the ﬁlamentous phage relies on the non-speciﬁc
modiﬁcation of the free amine groups of the phage coat pro-
teins. A number of strategies exist to target amines on proteins,
including the use of isothiocyanates, isocyanates, acyl azides,
and N-hydroxysuccinimide (NHS) esters (Hermanson, 2013). Of
these, the acylation of amines using NHS esters has seen the
most use. This reaction proceeds within an ideal pH range of
7.0–9.2 and results in the formation of a stable amide link-
age following NHS release (Figure 1B; Mujumdar et al., 1993).
Reports by several research groups have demonstrated that NHS
ester chemistry is a reliable strategy for modifying the virion
coat proteins (Table 1), although this approach can also lead
to unwanted acylation of the lysine residues on protein fusions.
For instance, Yacoby et al. (2006) demonstrated that both fd and
M13 phage could serve as targeted drug carriers. In this inter-
esting study, the phage scaffold was ﬁrst modiﬁed genetically
to include either a targeting peptide on the pVIII coat protein
or a fUSE5-ZZ IgG binding domain on the pIII coat protein.
Subsequently, the lysine residues were functionalized with chlo-
ramphenicol glutarate derivatives bearing additional NHS ester
groups for phage attachment. It was then demonstrated that
the phage-chloramphenicol constructs acted as prodrugs because
they did not have cytotoxic activity until the labile ester linkages
were released at the target site. Although the protein modiﬁca-
tion strategy proved to be successful overall, several complications
arose upon using free amine modiﬁcation to create this prodrug
phage construct. First, the researchers had to take the precau-
tion of selecting the targeting peptide displayed on pVIII such
that it did not contain a free lysine in its motif. Additionally, the
fuSE5-ZZ binding moiety displayed on the pIII protein had to be
protected with human protein A-puriﬁed IgG prior to being con-
jugated with the chloramphenicol derivatives. Another difﬁculty
that the researchers faced was that the high percentage of modiﬁ-
cation of the phage proteins caused them to become unstable and
insoluble.
To gain an improved understanding of phage coat proteinmod-
iﬁcation using NHS esters, Jin et al. (2009) developed an empirical
kinetic model to predict the modiﬁcation level of ﬁlamentous
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Table 1 | Functionalization of filamentous phage for application.
Application Modification strategies [G]: Genetic [C]: Chemical Functionalization Reference
Protein engineering [G] Peptide (pIII, pVIII) Native chemical ligation Dwyer et al. (2000)
Combinatorial library [G] Yeast acceptor peptide (pIII) Streptavidin-ﬂuorophore Chen et al. (2007)
Imaging [G] Sortase motif (pIII, pVIII) Single domain antibody,
ﬂuorescent peptide
Hess et al. (2012)
Immunoassays [G] Antigen binding site (pIII)[C] Thiol alkylation Fluorophore Jespers et al. (2004)
Combinatorial library [G] Peptide motif (pIII)[C] Thiol alkylation Small molecule Heinis et al. (2009)
Light-responsive ligands [G] Cysteine containing peptide (pIII)[C] Alkylation/reduction Photoresponsive azobenzene
core
Jafari et al. (2014)
Targeted binding [G] Cysteine containing peptide (pIII)[C] Maleimide EGFR-binding peptide Santoso et al. (2013)
Ligand identiﬁcation [G] N-terminal Ser/Thr (pIII)[C] Sodium periodate/oxime form. Glycan Ng et al. (2012)
Biosensor [G] Targeting peptide (pIII)[C] NHS ester Cy5 dye Goldman et al. (2000)
Imaging application [G] Targeting peptide (pIII, pVIII)[C] NHS ester Fluorochromes Hilderbrand et al. (2005)
Targeted drug delivery [G] Targeting peptide (pIII, pVIII)[C] NHS ester Chloramphenicol Yacoby et al. (2006)
pH-responsive imaging [C] NHS ester pH responsive dye Hilderbrand et al. (2008)
Composite ﬁbers [C] Lysine modiﬁcation Glutaric anhydride Niu et al. (2008)
NHS kinetic study [C] NHS ester AF680 Jin et al. (2009)
Cancer cell imaging [C] NHS ester, diazonium coupling Fluorescein, folate azide Li et al. (2010)
Drug delivery [C] NHS ester Folic acid Suthiwangcharoen et al. (2011)
Cancer cell imaging [G] scFv (pIII)[C] N-terminal transamination Small molecule, ﬂuorophore Carrico et al. (2012)
NMR biosensor [G] scFv (pIII)[C] N-terminal transamination 129Xe cryptophane-A Palaniappan et al. (2013)
phage under a wide range of reaction conditions. This study
found that ﬁfty percent of the phage maximum binding capacity
to streptavidin was reached when approximately 0.03 biotins were
attached per pVIII subunit. Such information can reduce the need
for over modifying a targeting construct in future studies, perhaps
allowing additional modiﬁcations to be used to append secondary
cargo and/or solubilizing moieties.
Subsequent studies by Li et al. (2010) screened the reactivity
of the amino groups of the virion by varying the concentra-
tion of N,N,N ′,N ′-tetramethylrhodamine (TMR) NHS ester in
a 24 h reaction. Through use of UV-visible spectroscopy, it
was found that 1600 rhodamine units could be attached to
the M13 bacteriophage, but ﬂuorescence quenching occurred
when the phage particles bore more than 400 dyes each. In
addition, the study elucidated that some of the six amines
present on the M13 pVIII protein (N-terminal alanine 1 and
lysines 8, 40, 43, 44, and 48) were more reactive than oth-
ers. At low levels of modiﬁcation, Ala-1 was primarily modiﬁed
and at high modiﬁcation levels both Ala-1 and Lys-8 were
modiﬁed.
As another example of using NHS esters to functionalize
phage, Li et al. (2010) created a construct for drug delivery
using an M13 particle assembly. This structure was function-
alized to bind cancer cells by using NHS ester chemistry to
attach folic acid. The group was able to demonstrate that each
pVIII subunit contained only one modiﬁcation, and that these
assemblies were amenable to loading with doxorubicin. More-
over, it was demonstrated that these constructs were stable under
physiological conditions, but disassembled upon being delivered
to the target site. This construct is just one of many examples that
demonstrate that free aminemodiﬁcationutilizingNHSchemistry
is a viable strategy for the creation of functionalized phage (See
Table 1).
TYROSINE MODIFICATION
Diazonium groups have long been known to react with a lysine,
tyrosine, and histidine residues (Higgins and Harrington, 1959).
These highly reactive diazonium groups can be used to mod-
ify tyrosine residues at pH values that are typically greater
than 8.5 through an electrophilic attack on the active pi sys-
tem of tyrosine (Figure 1C; Hermanson, 2013). The ability of
diazonium salts to modify the phage major coat proteins was
tested by Li et al. (2010). It was found that this strategy could
append approximately 400 biotin groups per phage particle. Mod-
iﬁcations occurred on the two tyrosine residues displayed on
the pVIII major coat proteins (Tyr 21 and Tyr 24), whereas
the lysine and histidine residues remained unmodiﬁed. This
study is an important demonstration of a chemical modiﬁca-
tion strategy that can be used to complement the more com-
monly used lysine modiﬁcation strategies. Experimental results
from this study demonstrated that lower levels of modiﬁcations
were achieved with the use of diazonium salt modiﬁcation (400
molecules per phage) instead of NHS ester modiﬁcation (1600
molecules per phage). It should be noted that this modiﬁcation
strategy non-speciﬁcally labels tyrosine moieties on the entire
phage scaffold and therefore may not be ideal in scenarios in
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which binding moieties contain tyrosines. The generation of
diazonium salts with nitrous acid also places some limits on
the functional groups that can be present on the group to be
attached.
CARBOXYLIC ACID MODIFICATION
Carbodiimide compounds, such as 1-ethyl-3-(-3-dimethylaminop
ropyl) carbodiimidehydrochloride (EDC)andN ′,N ′-dicyclohexyl
carbodiimide (DCC), are common bioconjugation reagents used
to activate carboxylic acid containing residues. These compounds
react with aspartate and glutamate residues to form O-acylisourea
intermediates, which subsequently react with primary amines
to form stable amide bonds, Figure 1D (Hermanson, 2013).
The reactivity of the carboxylic acid containing residues with
carbodiimide chemistry was investigated by Li et al. (2010). In
this study, varying concentrations of rhodamine B amine (RB),
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and N-
hydroxysulfosuccinimide (sulfo-NHS) were allowed to react with
the phage coat proteins during a 12 h incubation period. It was
found that the RB dye had a low degree of reactivity, and therefore
a small molecule analog, propargylamine, was used to identify
the reactive moieties. Of the four available carboxylic acid con-
taining sites, only two sites (Glu-2 and Asp4/Asp5) on the pVIII
monomers were found to be modiﬁed. The second modiﬁcation
site could not be distinguished between Asp4/Asp5 due to their
close proximity.
Successive studies done by Vaks and Benhar (2011), demon-
strated the capability of EDC coupling to functionalize the phage
scaffold as an anti-microbial agent. In this study, the ﬁlamentous
phage scaffoldwas covalently attached to chloramphenicol with an
aminoglycoside linker using EDC coupling. These modiﬁed phage
particles were shown to have prodrug qualities, longer circulation
times, and lower immunogenicity compared to wild type phage.
The studies described above demonstrate that EDC coupling
is a modiﬁcation strategy that can be used effectively to target
the carboxylic acid moieties on the phage scaffold to create new
phage materials. As shown by Li et al. (2010), these carboxylic acid
moieties are less chemically reactive than their lysine and tyrosine
amino acid counterparts, and so are likely to result in lower percent
modiﬁcation of the phage scaffold. Because EDC coupling is not
a site-speciﬁc chemical modiﬁcation strategy, any carboxyl entity
on a displayed protein is susceptible to modiﬁcation.
N-TERMINAL MODIFICATION
In an effort to move toward a site-selective modiﬁcation approach,
an N-terminal transamination modiﬁcation strategy has been
developed using pyridoxal 5′-phosphate (PLP) to functionalize
the phage (Carrico et al., 2012). This method involves a two-step
site-selective transamination/oxime-formation reaction, wherein
the N-terminal amine is transformed into a pyruvamide group
that is then converted into an oxime using alkoxyamine reagents
(Figure 1E). Through this chemistry, 80% of the pVIII N-termini
along the capsids could be converted to ketone functional groups,
as determined by HPLC. The reaction was found to be selective
for only solvent accessible N-terminal amines, with no participa-
tion from the ε-amine groups of lysine (Scheck et al., 2008). With
this chemistry, fd phage bearing single-chain antibody fragment
(scFv) groups previously determined to bind epidermal growth
factor receptor (EGFR; Heitner et al., 2001) and human EGFR 2
(HER2; Poul et al., 2000) were modiﬁed with ﬂuorophores and
polyethylene glycol 2k (PEG2k) to create phage constructs that
could distinguish breast cancer cell markers using ﬂuorescence
microscopy. Following this initial report, Palaniappan et al. (2013)
further explored the versatility of this chemistry to create phage
constructs for use as targeted 129Xe NMR biosensors. The use of
N-terminal transamination/oxime-formation for the functional-
ization of the phage scaffold provides one of the ﬁrst examples
of a site-selective method that has been used to modify the phage
coat proteins. This strategy provides a way to reach high levels of
modiﬁcation while preserving the binding capabilities of peptides
that are displayed in other positions. Through the use of strategies
such as these, well-deﬁned constructs withmultiple functionalities
can be obtained.
As an alternative, serine and threonine residues have also
been incorporated as latent N-terminal functional handles. The
Derda group has demonstrated the functionalization of the virion
through genetic introduction of a serine or threonine at the N-
terminus of the minor coat pIII proteins (Ng et al., 2012). These
phage were treated with sodium periodate to provide aldehydes,
allowing for the incorporation of glycan moieties through oxime
formation. Moreover, the Derda group further showed the power
of genetic incorporation to serve as an N-terminal functional han-
dle as they demonstrated that 2-amino benzamidoxime (ABAO)
derivatives could react with oxidized N-terminal serines present
on the pIII protein of the phage (Kitov et al., 2014). This latter
strategy can be used to functionalize the pIII minor coat proteins
directly.
CONCLUSION AND FUTURE DIRECTIONS
The chemical modiﬁcation strategies described in this review
showcase the current methods that have been used to create
promising constructs; however, they also highlight many of the
challenges of this ﬁeld. Genetic modiﬁcations have allowed for
the introduction of peptide motifs and natural amino acids that
can act as handles for phage functionalization. In addition to the
genetic incorporation of natural amino acids, unnatural amino
acids have also been shown to be incorporated (Chen et al.,
2007; Liu et al., 2008). With the new functional groups that this
technique introduces comes a substantially expanded range of
reactions that can be used to functionalize the phage by targeting
uniquely reactive moieties such as ketones, azides, and alkynes.
This will undoubtedly yield many selective modiﬁcation strate-
gies in the future. However, one major hurdle in using genetic
approaches such as these is that the successes of these strategies
are highly dependent on the ability of the phage coat proteins to
tolerate genetic modiﬁcations.
The bioconjugation toolbox for phage functionalization is still
limited in its ability to modify the scaffold under reaction con-
ditions that will keep the construct functional. Commonly used
bioconjugation techniques, such as NHS ester, EDC, and diazo-
nium chemistry, have limited degrees of site-selectivity and can be
difﬁcult to control in terms of the modiﬁcation they can achieve.
If high levels of modiﬁcations are to be attempted, these chemi-
cal modiﬁcations can result in over-modiﬁcation of the scaffold,
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rendering displayed peptides inactive and/or desolubilizing and
destabilizing the construct. Site-selective bioconjugation strate-
gies allow for the development of more well-deﬁned constructs,
which can obtain high levels of site-speciﬁc modiﬁcation and still
maintain function.
Although untested in the context of ﬁlamentous phage, a num-
ber functionalization strategies may prove to be effective tools in
creating well-deﬁned phage constructs. For example, enzymatic
modiﬁcations such as those developed by Carrico et al. (2007) may
allow for the incorporation of a chemical functional handle onto
the phage scaffold. In addition to this, chemical strategies that tar-
get tyrosine residues could be applied, such as palladium pi-allyl
chemistry (Tilley and Francis, 2006), Mannich reactions (Joshi
et al., 2004), oxidative couplings (Seim et al., 2011), and a new
tyrosine-click reaction (Ban et al., 2013). These strategies could
expand the functional group tolerance beyond that of diazonium
coupling reactions. Moreover, site-speciﬁc protein transamination
using N-methylpyridinium-4-carboxaldehyde (Rapoport’s Salt)
to introduce a carbonyl can be seen as a promising chemical
modiﬁcation strategy for the ﬁlamentous phage as the major coat
protein pVIII contains a glutamate-rich sequence that is predicted
to be reactive for this reagent (Witus et al., 2013). This strategy
shows potential for achieving higher levels of modiﬁcations of the
pVIII coat proteins that may be advantageous for a number of
applications.
Despite the advances that have been made in phage function-
alization, it is still generally difﬁcult to construct scaffolds that
can be modiﬁed in multiple locations in a well-deﬁned man-
ner. Future advances in the development of phage constructs
will most likely focus on the development of combined genetic
and chemical strategies that will allow for site-speciﬁc incor-
poration of multiple functionalities onto the virion. Although
genetic engineering approaches have been shown to be power-
ful tools to display peptide functionalities on the phage scaffold,
complementary chemical modiﬁcation strategies can offer simple
and reliable methods for appending widely varying function-
alities to provide access to a wider variety of multifunctional
materials.
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